Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy

CONTEXT: We describe the clinical investigation of the first generation aldosterone synthase inhibitor, LCI699, in patients with essential, uncontrolled, resistant, or secondary hypertension. LCI699 competitively reduced blood pressure at lower doses yet counterintuitive effects were observed at hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Schumacher, Christoph D., Steele, Ronald E., Brunner, Hans R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
ORIGINAL PAPERS: Therapeutic aspects
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771574/
https://www.ncbi.nlm.nih.gov/pubmed/24107737
http://dx.doi.org/10.1097/HJH.0b013e328363570c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771574/
https://www.ncbi.nlm.nih.gov/pubmed/24107737
http://dx.doi.org/10.1097/HJH.0b013e328363570c

Ejemplares similares